NCT05673902 - Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 11, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Idiopathic Recurrent Pericarditis

Interventions

BIOLOGICAL

RPH-104

solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Trial Locations (1)

National medical research center named after V. A. Almazov, Saint Petersburg